The Cholesterol Paradox Revisited: Heart Failure, Systemic Inflammation, and Beyond

Heart Failure Clinics

Volumn 4, Issue 2, 2008, Pages 141-151

  von Haehling, Stephan ^a,b   Schefold, Joerg C ^a   Springer, Jochen ^a   Anker, Stefan D ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOKINE; ENDOTOXIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HLA DR ANTIGEN; LIPOPOLYSACCHARIDE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

AUTHOR; BACTERIUM; CLINICAL TRIAL; CORRELATIONAL STUDY; DESENSITIZATION; DOWN REGULATION; DRUG ACTIVITY; DRUG DOSE INCREASE; HEART FAILURE; HUMAN; HYPOTHESIS; INFLAMMATION; LIPID BLOOD LEVEL; MEDICAL INFORMATION; MICELLIZATION; MORBIDITY; MORTALITY; NONHUMAN; PLEIOTROPY; PREVALENCE; PROSPECTIVE STUDY; PUBLIC HEALTH; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SURVIVAL; UPREGULATION;

CHOLESTEROL; HEART FAILURE; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; SEPSIS; SIGNAL TRANSDUCTION;

EID: 42149143091     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.01.009     Document Type: Review

References (102)

1. Cowie M.R., Mosterd A., Wood D.A., et al. The epidemiology of heart failure. Eur Heart J 18 (1997) 208-225
2. Davies M., Hobbs F., Davis R., et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 358 (2001) 439-444
3. Hunt S.A., Baker D.W., Chin M.H., et al., American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
4. Meerding W.J., Bonneux L., Polder J.J., et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 317 (1998) 111-115
5. O'Connell J.B., and Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 13 (1994) S107-S112
6. McMurray J.J., and Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 83 (2000) 596-602
7. Remme W.J., McMurray J.J., and Rauch B. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J 26 (2005) 2413-2421
8. Stewart S., MacIntyre K., Hole D.J., et al. More malignant than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 22 (2001) 315-322
9. Remme W.J., and Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
10. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110 (2004) 1042-1046
11. Rosamond W., Flegal K., Furie K., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
12. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
13. von Haehling S., Genth-Zotz S., Anker S.D., et al. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol 85 (2002) 173-183
14. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 (2005) 1019-1026
15. Sharma R., Francis D.P., Pitt B., et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25 (2004) 1021-1028
16. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 (2006) 1440-1446
17. Witte K.K., Nikitin N.P., Parker A.C., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26 (2005) 2238-2244
18. Jankowska E.A., Ponikowski P., Piepoli M.F., et al. Autonomic imbalance and immune activation in chronic heart failure: pathophysiological links. Cardiovasc Res 70 (2006) 434-445
19. Krack A., Sharma R., Figulla H.R., et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26 (2005) 2368-2374
20. Conraads V.M., Jorens P.G., De Clerck L.S., et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 6 (2004) 483-491
21. Sandek A., Bauditz J., Swidsinski A., et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50 (2007) 1561-1569
22. Anker S.D., and Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 85 (2002) 51-66
23. von Haehling S., Doehner W., and Anker S.D. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73 (2007) 298-309
24. Anker S.D., and Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86 (2002) 123-130
25. von Haehling S., Jankowska E.A., and Anker S.D. Tumour necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol 99 (2004) 18-28
26. von Haehling S., and Anker S.D. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 14 (2005) 163-176
27. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
28. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72 (1994) 561-566
29. Tsutamoto T., Hisanaga T., Wada A., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
30. Genth-Zotz S., von Haehling S., Bolger A.P., et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 90 (2002) 1226-1230
31. Triantafilou M., and Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23 (2002) 301-304
32. Földes G., von Haehling S., and Anker S.D. Toll-like receptor modulation in cardiovascular disease: a target for intervention?. Expert Opin Investig Drugs 15 (2006) 857-871
33. da Silva Correia J., Soldau K., Christen U., et al. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: transfer from CD14 to TLR4 and MD-2. J Biol Chem 276 (2001) 21129-21135
34. Shimazu R., Akashi S., Ogata H., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189 (1999) 1777-1782
35. Triantafilou K., Triantafilou M., and Dedrick R.L. A CD14-independent LPS receptor cluster. Nat Immunol 2 (2001) 338-345
36. Triantafilou M., and Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide. Biochem Soc Trans 32 (2004) 636-639
37. Genth-Zotz S., Bolger A.P., Kalra P.R., et al. Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. Int J Cardiol 96 (2004) 397-401
38. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842
39. Axtelle T., and Pribble J. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res 7 (2001) 310-314
40. Verbon A., Dekkers P.E., ten Hove T., et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 166 (2001) 3599-3605
41. Manocha S., Feinstein D., Kumar A., et al. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 11 (2002) 1795-1812
42. Rauchhaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
43. Horwich T.B., Hamilton M.A., Maclellan W.R., et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
44. Horwich T.B., and Fonarow G.C. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 20 (2007) 549-553
45. Sharma R., von Haehling S., Bolger A.P., et al. Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. Eur J Heart Fail 7 (2005) 479-484
46. Gordon B.R., Parker T.S., Levine D.M., et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 24 (1996) 584-589
47. Murch O., Collin M., Hinds C.J., et al. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 33 (2007) 13-24
48. Wu A., Hinds C.J., and Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21 (2004) 210-221
49. Sammalkorpi K., Valtonen V., Kerttula Y., et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 37 (1988) 859-865
50. Windler E., Ewers-Grabow U., Thiery J., et al. The prognostic value of hypocholesterinemia in hospitalized patients. Clin Investig 72 (1994) 939-943
51. Chien J.Y., Jerng J.S., Yu C.J., et al. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33 (2005) 1688-1693
52. van Leeuwen H.J., Heezius E.C., Dallinga G.M., et al. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31 (2003) 1359-1366
53. Rauchhaus M., Coats A.J., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 (2000) 930-933
54. Flegel W.A., Baumstark M.W., Weinstock C., et al. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 61 (1993) 5140-5146
55. Harris H.W., Grunfeld C., Feingold K.R., et al. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 86 (1990) 696-702
56. Levine D.M., Parker T.S., Donnelly T.M., et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 90 (1993) 12040-12044
57. Netea M.G., de Bont N., Demacker P.N., et al. Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells. Infect Immun 66 (1998) 2365-2367
58. Read T.E., Grunfeld C., Kumwenda Z.L., et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med 182 (1995) 267-272
59. Emancipator K., Csako G., and Elin R.J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 60 (1992) 596-601
60. Hubsch A.P., Casas A.T., and Doran J.E. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 126 (1995) 548-558
61. Feingold K.R., Funk J.L., Moser A.H., et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 63 (1995) 2041-2046
62. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33 (1992) 1569-1582
63. von Haehling S., Okonko D.O., and Anker S.D. Statins: a treatment option for chronic heart failure?. Heart Fail Monit 4 (2004) 90-97
64. Page C.P., Curtis M.J., Sutter M.C., et al. Integrated pharmacology (1997), Mosby, St. Louis (MO) p. 267-70
65. Shepherd J., Cobbe S.M., Ford I., et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
66. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
67. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomised controlled trial. JAMA 285 (2001) 1711-1718
68. Vaughan C.J., Gotto A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
69. von Haehling S., Anker S.D., and Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev 8 (2003) 99-106
70. von Haehling S., and Anker S.D. Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?. Heart 91 (2005) 1-2
71. Walter D.H., Dimmeler S., and Zeiher A.M. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med 4 (2004) 385-393
72. Aznar S., and Lacal J.C. Rho signals to cell growth and apoptosis. Cancer Lett 165 (2001) 1-10
73. Anker S.D., Clark A.L., Winkler R., et al. Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients. Int J Cardiol 112 (2006) 234-242
74. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
75. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
76. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
77. Yamada T., Node K., Mine T., et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153 (2007) 1055 e1-e8
78. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47 (2006) 338-341
79. Gürgün C., Ildizli M., Yavuzgil O., et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 123 (2008) 102-107
80. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13 (2007) 1-7
81. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
82. Döcke W.D., Randow F., Syrbe U., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3 (1997) 678-681
83. Sharma R., Bolger A.P., Rauchhaus M., et al. Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail 7 (2005) 865-868
84. Volk H.D., Reinke P., Krausch D., et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 (1996) S474-S481
85. von Haehling S., Jankowska E.A., Foldes G., et al. Attenuated specific immunity in chronic heart failure. [abstract]. Eur Heart J 26 Suppl 1 (2005) 326
86. Annane D., Bellissant E., and Cavaillon J.M. Septic shock. Lancet 365 (2005) 63-78
87. Terblanche M., Almag Y., Rosenson R., et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 7 (2007) 358-368
88. Ando H., Takamura T., Ota T., et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294 (2000) 1043-1046
89. Merx M.W., Liehn E.A., Graf J., et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112 (2005) 117-124
90. Hackam D.G., Mamdani M., Li P., et al. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367 (2006) 413-418
91. Almog Y., Shefer A., Novack V., et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110 (2004) 880-885
92. Majumdar S.R., McAlister F.A., Eurich D.T., et al. Statins and outcomes in patients admitted to hospital and community acquired pneumonia: population based prospective cohort study. BMJ 333 (2006) 999-1003
93. Martin C.P., Talbert R.L., Burgess D.S., et al. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27 (2007) 20-26
94. van de Garde E.M., Hak E., Souverein P.C., et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 61 (2006) 957-961
95. Mortensen E.M., Restrepo M.I., Anzueto A., et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 25 (2005) 82-88
96. Gupta R., Plantinga L.C., Fink N.E., et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA 297 (2007) 1455-1464
97. Thomsen R.W., Hundborg H.H., Johnsen S.P., et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 34 (2006) 1080-1086
98. Monneret G., Lepape A., Voirin N., et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32 (2006) 1175-1183
99. Reith W., LeibundGut-Landmann S., and Waldburger J.M. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5 (2005) 793-806
100. Schefold J.C., von Haehling S., Corsepius M., et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 28 (2007) 418-425
101. Nierhaus A., Montag B., Timmler N., et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 4 (2003) 646-651
102. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455